Compare · AZN vs FWP
AZN vs FWP
Side-by-side comparison of AstraZeneca PLC (AZN) and Forward Pharma A/S (FWP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and FWP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN carries a market cap of $285.36B.
- AZN has hit the wire 22 times in the past 4 weeks while FWP has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 0 for FWP).
- Company
- AstraZeneca PLC
- Forward Pharma A/S
- Price
- -
- -
- Market cap
- $285.36B
- -
- 1M return
- +11.24%
- -
- 1Y return
- +105.93%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2014
- News (4w)
- 22
- 0
- Recent ratings
- 25
- 0
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Forward Pharma A/S
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. The company was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- SEC Form 6-K filed by AstraZeneca PLC
Latest FWP
- SEC Form SC 13G/A filed by Forward Pharma A/S (Amendment)
- SEC Form EFFECT filed by Forward Pharma A/S
- SEC Form POS AM filed by Forward Pharma A/S
- SEC Form S-8 POS filed by Forward Pharma A/S
- SEC Form S-8 POS filed by Forward Pharma A/S
- SEC Form 15-12G filed by Forward Pharma A/S
- SEC Form 6-K filed by Forward Pharma A/S
- SEC Form 25-NSE filed by Forward Pharma A/S
- SEC Form SC 13G filed by Forward Pharma A/S
- SEC Form 6-K filed by Forward Pharma A/S